Clinical and laboratory results from adeptTM 1, a phase 2 trial investigating the use of recombinant activated FVII analogue in congenital haemophilia patients with inhibitors
JOURNAL OF THROMBOSIS AND HAEMOSTASIS（2011）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要